Saxenda FDA Approval History
Saxenda (liraglutide) is a once-daily glucagon-like peptide-1 (GLP-1) analogue for the treatment of obesity.
Development Timeline for Saxenda
|Dec 4, 2020||Approval FDA Approves Saxenda (liraglutide) for the Treatment of Obesity in Adolescents Aged 12-17|
|Dec 23, 2014||Approval FDA Approves Saxenda (liraglutide [rDNA origin] injection) for Obesity|
|Sep 11, 2014||FDA Advisory Committee Votes 14-1 in Favor of Saxenda (liraglutide) for Obesity|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.